N-Acetyl Semax Amidate is a modified form of Semax, a synthetic heptapeptide developed in Russia. The base sequence is the same: Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). What changes are the two ends of the molecule. An acetyl group is added to the N-terminus and an amide group caps the C-terminus. Vendors list it under CAS 2920938-90-3 and catalog codes like HY-P3588.
Start with the parent, because that is where nearly all the evidence lives.
What Semax is
Semax is a synthetic analogue of a fragment of adrenocorticotropic hormone, specifically the ACTH(4-10) region, with a Pro-Gly-Pro tail bolted on to slow enzymatic breakdown. It was first described in the literature around 1991 and is on the Russian Federation's List of Vital and Essential Drugs. In Russia and some neighboring countries it is a prescription product used for conditions including ischemic stroke, transient ischemic attack, and cognitive disorders, per the Wikipedia overview and a pharmacology review of ACTH(4-7)PGP. Unlike full ACTH, it does not stimulate adrenal steroid output.
It has never been evaluated or approved by the FDA, EMA, or Health Canada.
Proposed mechanism
Two lines of explanation show up in the animal literature. In rats, Semax raises brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the hippocampus; a 2003 in vivo study in rats reported increased BDNF expression across several brain regions. Separate rodent work found it activates dopaminergic and serotonergic systems (Eremin et al., 2005). As an ACTH fragment it also interacts with melanocortin receptors and appears to slow enkephalin-degrading enzymes. These are mechanisms documented mostly in animals and cell systems, not settled human pharmacology.
Where the N-acetyl amidate variant fits
Here is the honest part. The acetylation and amidation are chemical stabilizing changes intended to resist enzymatic cleavage and extend how long the peptide stays intact. That is a reasonable rationale on paper. But published, peer-reviewed research specifically on N-Acetyl Semax Amidate as its own compound is thin. The clinical track record, the stroke data, the BDNF findings all belong to standard Semax. Claims that the amidate version is meaningfully stronger or longer-acting in humans are not backed by trials you can point to. Treat vendor descriptions of enhanced potency as marketing, not data.
Suppliers sell it explicitly as a research chemical, not for human use.
For buyers: identity and testing
This is a research-use-only material, not an approved drug or supplement, and nothing here is medical or dosing advice. Because the modification is subtle (two terminal groups on an otherwise identical seven-residue chain), identity matters: a label reading "N-acetyl semax amidate" could be plain Semax, the amidate, or something off-spec, and you cannot tell by looking. A current third-party certificate of analysis covering identity (mass spec) and purity (HPLC), tied to the specific lot, is the only way to know what is in a vial. peptideone aggregates vendor COAs and independent rater signals so you can compare that documentation across sellers rather than taking a product page at its word.
WADA note
Semax is not specifically named on the World Anti-Doping Agency Prohibited List, but WADA rules cover whole classes of substances and change yearly. Athletes should check the current list directly rather than rely on a peptide's absence by name.